In Phase II trials of cetuximab treatment in patients with epidermal growth factor receptor (EGFR) positive refractory colorectal cancer, more than 86% of patients developed acne-like skin rash, including 18% developing grade 3 symptoms (26). This evidence concerns the gene EGFR and Skin rash.